36 Matching Annotations
  1. Oct 2022
    1. In the interest of reducing warranty claims (which are much more expensive than that incremental manufacturing cost) carmakers are sizing the whole unit to reliably accommodate the worst case draw (driver turns everything on at the same time, at idle).
  2. Aug 2022
  3. Feb 2022
    1. F. Perry Wilson, MD MSCE. (2022, February 4). If you, like me, are “skipping ahead” during the ACIP meeting re: Moderna vaccine—This slide really drives home the benefit / risk paradigm among the group at highest risk of myocarditis (men 18-35). 2 million shots = 1903 avoided hospitalizations, and 68 myocarditis cases. Https://t.co/3nzWXGXyD1 [Tweet]. @fperrywilson. https://twitter.com/fperrywilson/status/1489649379979972609

  4. Nov 2021
  5. Oct 2021
  6. Aug 2021
  7. Jul 2021
    1. Gargano, J. W., Wallace, M., Hadler, S. C., Langley, G., Su, J. R., Oster, M. E., Broder, K. R., Gee, J., Weintraub, E., Shimabukuro, T., Scobie, H. M., Moulia, D., Markowitz, L. E., Wharton, M., McNally, V. V., Romero, J. R., Talbot, H. K., Lee, G. M., Daley, M. F., & Oliver, S. E. (2021). Use of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from the Advisory Committee on Immunization Practices — United States, June 2021. MMWR. Morbidity and Mortality Weekly Report, 70(27), 977–982. https://doi.org/10.15585/mmwr.mm7027e2

  8. Jun 2021
  9. May 2021
  10. Apr 2021
  11. Dec 2020
  12. Oct 2020
  13. Aug 2020
  14. Jul 2020
  15. Apr 2020
    1. “Even if experts are saying it’s really not going to make a difference, a little [part of] people’s brains is thinking, well, it’s not going to hurt. Maybe it’ll cut my risk just a little bit, so it’s worth it to wear a mask,” she says.
  16. May 2019
    1. first target the patients at highest risk of relapse;

      Clinical trials will most certainly first include those patients with the highest risk of relapse. However, long term, everything will depend on the risk/ benefit trade off: if an effective, simple, well-tolerated and cost-effective treatment was available (let's imagine a single short low-dose PD1 for any early Melanoma patient) that prevented progression for most patients would be very different from a highly toxic, expensive treatment that doesn't work for everyone (think Ipi 10mg/kg adjuvant)- so everything is in the trade-off

  17. Dec 2016